Abstract: Aspects of the disclosure provide controlling an autonomous vehicle. For example, a first trajectory generated by a first planning system may be received. A portion of the first trajectory may be input into a second planning system. A second trajectory generated by the second planning system based on the portion of the first trajectory may be received. The second trajectory may be used to determine whether to validate the first trajectory, and when the second trajectory is determined to be validated, the autonomous vehicle may be enabled to be controlled based on the first trajectory.

Abstract: Aspects of the disclosure provide controlling an autonomous vehicle. For example, a first trajectory generated by a first planning system may be received. A portion of the first trajectory may be input into a second planning system. A second trajectory generated by the second planning system based on the portion of the first trajectory may be received. The second trajectory may be used to determine whether to validate the first trajectory, and when the second trajectory is determined to be validated, the autonomous vehicle may be enabled to be controlled based on the first trajectory.

Abstract: An example computer implemented method includes sending a first data package from a central computing entity to a local computing entity that includes (1) dependency check instructions and (2) partition instructions. The local computing entity executes the instructions to determine runtime dependencies, divide a memory into a first partition and a second partition, and move an existing operating system instruction set and user data to the first partition of the memory. The method further includes receiving a confirmation signal at the central computing entity indicative of the runtime dependencies and that the local computing entity formed the partitions in the memory, and subsequently sending a second data package to install a second operating system instruction set on the local computing entity. Following, the method includes monitoring progress of installation of the second operating system instruction set on the local computing entity.

Abstract: Aspects of the disclosure provide controlling an autonomous vehicle. For example, a first trajectory generated by a first planning system may be received. A portion of the first trajectory may be input into a second planning system. A second trajectory generated by the second planning system based on the portion of the first trajectory may be received. The second trajectory may be used to determine whether to validate the first trajectory, and when the second trajectory is determined to be validated, the autonomous vehicle may be enabled to be controlled based on the first trajectory.

Abstract: Described herein are compositions of an linoleic phospholipid for inhibiting inflammatory pathways or neurodegenerative processes. Also provided are uses of such compositions and methods of inhibiting inflammatory or neurodegenerative processes by administering a composition that includes an linoleic phospholipid and optionally a carrier to a cell, cell culture or subject in need of such treatment.

Abstract: Described herein are compositions of an linoleic phospholipid for inhibiting inflammatory pathways or neurodegenerative processes. Also provided are uses of such compositions and methods of inhibiting inflammatory or neurodegenerative processes by administering a composition that includes an linoleic phospholipid and optionally a carrier to a cell, cell culture or subject in need of such treatment.

Abstract: The present invention provides combinations of pharmaceutically active agents (i.e. statins and negatively charged phospholipids) for treating or preventing atherosclerosis or coronary artery disease (CAD) in mammals, and methods therefore. In particular, these combinations and methods find utility for achieving one or more of the following effects in a subject: (1) a reduction in plasma levels of low-density lipoprotein (LDL) cholesterol and very-low-density lipoprotein (VLDL) cholesterol; (2) an increase in plasma levels of high-density lipoprotein (HDL) cholesterol; and (3) a reduction in plasma levels of triglycerides.

Abstract: The present invention provides pharmaceutical compositions and methods for raising plasma levels of apolipoprotein A-I in a mammal, e.g. for treating or preventing coronary artery disease (CAD). The inventive pharmaceutical compositions comprise: (a) a negatively charged phospholipid; and (b) at least one intestinal absorption enhancer; where (a) and (b) are present in such composition in amounts that render the combination effective for raising plasma levels of apolipoprotein A-I in a mammal. Also provided are corresponding methods of medical treatment comprising administering to a mammal: (a) a negatively charged phospholipid; and (b) at least one intestinal absorption enhancer; where (a) and (b) are administered in amounts that render the combination effective for raising plasma levels of apolipoprotein A-I in said mammal.

Abstract: The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.

Abstract: The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.